Lack of cross-reactivity of Ambien (zolpidem) with drugs in standard urine drug screens

Archives of Pathology and Laboratory Medicine

Volumn 121, Issue 4, 1997, Pages 392-394

  Piergies, A A ^a,d   Sainati, S ^b   Roth Schechter, B ^c  

^a Evanston Northwestern Hospital   (United States)

^b Lorex Pharmaceuticals   (United States)

^c Boston Res and Science Consulting   (United States)

^d EVANSTON HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE DERIVATIVE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABINOID DERIVATIVE; COCAINE; DRUG METABOLITE; OPIATE DERIVATIVE; TEMAZEPAM; ZOLPIDEM TARTRATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DROWSINESS; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG CROSS REACTIVITY; DRUG HALF LIFE; DRUG SCREENING; DRUG URINE LEVEL; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INSOMNIA; MALE; NORMAL HUMAN; RHINITIS; SALPINGITIS; TASTE DISORDER;

ADOLESCENT; ADULT; CROSS REACTIONS; DRUG INTERACTIONS; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FALSE POSITIVE REACTIONS; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PYRIDINES; REAGENT KITS, DIAGNOSTIC; SUBSTANCE ABUSE DETECTION; TEMAZEPAM;

EID: 0030968037     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Coffman NB, Fernandes J. Drugs of abuse testing. I Am Osteopathol Assoc. 1991;91:385-396.
2. Liu RH. Comparison of common immunoassay kits for effective application in workplace drug urinalysis. Forensic Sei Rev. 1994;6:20-S7.
3. Camara PD, Audette L, Velletri K, et al. False positive immunoassay results for urine benzodiazepine in patients receiving oxapozin (Daypro). Clin Chem. 1995;41:115-116.
4. Ambien product information. In: Arky R, ed. Physician's Desk Reference. 49th éd. Montvale, N): Medical Economics Press; 1995:2304-2307.
5. Scharf MF, Roth T, Vogel GW, Walsh JK. A multicenter placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. I Clin Psychiatry. 1994;55:192-199.
6. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Steep. 1995;18:246-251.
7. Scharf MB, Mendels |, Thorpy M, Weiss B. Safety of long-term zolpidem treatment in patients with insomnia. Curr Ther Res. 1994:55:1100-1111.
8. Scharf MB, Mayleben DW, Kaffeman ME, Krall R, Ochs R. Dose response effects of zolpidem in normal geriatric subjects. I Clin Psychiatry. 1991;52:77-83.
9. Thénot JP, Hermann P, Durand A, et al. Pharmacokinetics and metabolism of zolpidem in various animal species and in humans. In: Sauvanet JP, Langer SZ, Morselli PL, eds. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. New York, NY: Raven Press; 1988:139-153.
10. Roehrs T, Vogel G, Sterling W, Roth T. Dose effects of temazepam in transient insomnia. Drug Res. 1990;40(pt 11, no. 8):859-862.
11. Fraschini F, Stankov B. Temazepam: pharmacological profile of a benzodiazepine and new trends in clinical application. Pharmacol Res. 1993:27:97-113.
12. George P, Rossey G, Depoortere H, et al. Zolpidem and related compounds: syntheses, physical properties and structure-activity relationships. In: Sauvanet )P, Langer SL, Morselli PL, eds. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. New York, NY: Raven Press; 1988:11-23.
13. Langer SZ, Arbilla S, Scatton B, et al. Receptors involved in the mechanism of action of zolpidem. In: Sauvanet JP, Langer SL, Morselli PL, eds. Imidazopyridines in Sleep Disorders: A Novel Experimental and Therapeutic Approach. New York, NY: Raven Press; 1988:55-70.
14. G. D. Searle, Inc. Monthly prescription volume trend data, 1/1/95-8/31/ 96. IMS America, Plymouth Meeting, Pa.
15. Guinebault P, Dubruc C, Hermann P, Thénot JP. High-performance liquid Chromatographie determination of zolpidem, a new sleep inducer, in biological fluids with fluorimetric detection. ; Chromatogr. 1986;383:206-211.
16. Hollander M, Wolfe D. Nonparametric Statistical Methods. New York, NY: John Wiley & Sons; 1987:23-24.
17. Beck O, Latolie P, Hjemdahl P, et al. Detection of benzodiazepine intake in therapeutic doses by immunoanalysis of urine: two techniques evaluated and modified for improved performance. Clin Chem. 1992:38:271-275.
18. Koch TR, Raglin RL, Kirk S, Bruni JF. Improved screening for benzodiazepines metabolites in urine using the Triage Panel for Drugs of Abuse. I Anal Toxicol. 1994;! 8:168-172.
19. Simonsson P, Lindberg J. The effect of beta-glucuronidase on urinary benzodiazepine concentrations as measured by FP1A benzodiazepine assay. Scand] Clin Lab Invest. 1994;54(suppl 218):74.